Exploring Phage Therapy as an Alternative to Antibiotics in Treating Multidrug-Resistant Bacterial Infections

Authors

  • Bernaitis L* Associate professor, Department of Microbiology, Nandha Siddha Medical College and Hospital, Erode-638052. Author
  • Nidhyashree V Under graduate, Nandha Siddha Medical College and Hospital, Erode-638052. Author
  • Shri Shanmathi K Under graduate, Nandha Siddha Medical College and Hospital, Erode-638052. Author
  • Dhana Packiya Lakshmi B Under graduate, Nandha Siddha Medical College and Hospital, Erode-638052. Author
  • Dhanalakshmi M Under graduate, Nandha Siddha Medical College and Hospital, Erode-638052. Author

Keywords:

Multidrug-resistant bacteria, bacteriophage, phage therapy, antibiotic resistance, biofilms, alternative therapies

Abstract

Multidrug-resistant (MDR) bacterial infections have become an escalating global health crisis, significantly limiting the effectiveness of antibiotics. With rising resistance rates, the need for alternative treatment strategies is more critical than ever. Phage therapy, which utilizes bacteriophages—viruses that specifically target and kill bacteria—has emerged as a promising alternative. Phages offer a highly specific mechanism of action and can be used synergistically with antibiotics to improve treatment efficacy. Advances in phage engineering, delivery methods, and their combination with antibiotics enhance their therapeutic potential, particularly against MDR pathogens. However, challenges such as phage resistance, regulatory barriers, and delivery efficiency remain. This review explores the mechanisms of phage action, clinical applications in MDR infections, and the future directions in phage therapy research.

 

References

1. World Health Organization. Antimicrobial resistance. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.

2. Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J. A., Klugman, K., & Davies, S. (2016). Access to effective antimicrobials: a worldwide challenge. The Lancet, 387(10014), 168-175. doi:10.1016/S0140-6736(15)00474-2.

3. Chaudhari, N. M., Gautam, A., Gupta, V. K., Kaur, G., Dutta, C., & Paul, S. (2018). PanGFR-HM: a dynamic web resource for pan-genomic and functional profiling of human microbiome with comparative features. Frontiers in microbiology, 9, 2322. doi:10.3389/fmicb.2018.02322.

4. Abedon, S. T., García, P., Mullany, P., & Aminov, R. (2017). Phage therapy: past, present and future. Frontiers in microbiology, 8, 981. doi:10.3389/fmicb.2017.00981.

5. Górski A, Międzybrodzki R, Weber-Dąbrowska B, et al. (2019). Phage Therapy: Combating Infections with a Naturally Occurring Virus. Front Microbiol. 10:330. doi:10.3389/fmicb.2019.00330.

6. Lin, D. M., Koskella, B., & Lin, H. C. (2017). Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World journal of gastrointestinal pharmacology and therapeutics, 8(3), 162. doi:10.4292/wjgpt.v8.i3.162.

7. Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. Future microbiology, 8(6), 769-783. doi:10.2217/fmb.13.47.

8. Nilsson, A. S. (2014). Phage therapy—constraints and possibilities. Upsala journal of medical sciences, 119(2), 192-198. doi:10.3109/03009734.2014.896438.

9. Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. Microbiology and molecular biology reviews, 74(3), 417-433. doi:10.1128/MMBR.00016-10

10. Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011). Phage treatment of human infections. Bacteriophage, 1(2), 66-85. doi:10.4161/bact.1.2.15845

11. Labrie, S. J., Samson, J. E., & Moineau, S. (2010). Bacteriophage resistance mechanisms. Nature Reviews Microbiology, 8(5), 317-327. doi:10.1038/nrmicro2315

12. Harper, D. R., Parracho, H. M., Walker, J., Sharp, R., Hughes, G., Werthén, M., ... & Morales, S. (2014). Bacteriophages and biofilms. Antibiotics, 3(3), 270-284. doi:10.3390/antibiotics3030270

13. Dedrick, R. M., Guerrero-Bustamante, C. A., Garlena, R. A., Russell, D. A., Ford, K., Harris, K., ... & Spencer, H. (2019). Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nature medicine, 25(5), 730-733. doi:10.1038/s41591-019-0437-z

14. Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. Future microbiology, 8(6), 769-783. doi:10.2217/fmb.13.47

15. Lin, D. M., Koskella, B., & Lin, H. C. (2017). Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World journal of gastrointestinal pharmacology and therapeutics, 8(3), 162. doi:10.4292/wjgpt.v8.i3.162

16. Oechslin, F. (2018). Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses, 10(7), 351. doi:10.3390/v10070351

17. Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019). Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell host & microbe, 25(2), 219-232. doi:10.1016/j.chom.2019.01.014

Downloads

Published

2024-11-21

Issue

Section

Articles

How to Cite

[1]
Bernaitis L*, Nidhyashree V, Shri Shanmathi K, Dhana Packiya Lakshmi B, and Dhanalakshmi M, Trans., “Exploring Phage Therapy as an Alternative to Antibiotics in Treating Multidrug-Resistant Bacterial Infections”, WJAMS, vol. 1, no. 2, pp. 12–14, Nov. 2024, Accessed: Mar. 23, 2026. [Online]. Available: https://wasrpublication.com/index.php/wjams/article/view/29